Independent Data Monitoring Committee Recommends Completion of PICASSO 3 Trial as Conducted for ZIOPHARM’s Palifosfamide in First-Line Soft Tissue Sarcoma

Independent Data Monitoring Committee Recommends Completion of PICASSO 3 Trial as Conducted for ZIOPHARM’s Palifosfamide in First-Line Soft Tissue Sarcoma

[at noodls] – – Independent Committee Concludes Progression-Free Survival Data From PICASSO 3 Trial Projected in First Quarter of 2013 – – Company to Host Update Call at 5:00 PM EST Today – NEW YORK, Nov. 14, 2012 (GLOBE … more

View todays social media effects on ZIOP

View the latest stocks trending across Twitter. Click to view dashboard

Share this post